| INTRODUC TI ON
Conjunctival melanoma (CoM) is a rare but potentially fatal ocular cancer (Kenawy, Lake, Coupland, & Damato, 2013) . Local CoM recurrence occurs in 5%-26% of cases after local excision and brachytherapy with/without cryotherapy (Damato & Coupland, 2009; Missotten, Keijser, De Keizer, & De Wolff-Rouendaal, 2005; Shields et al., 2000; Werschnik & Lommatzsch, 2002) ; however, recurrence occurs in over 50% when treated with surgical excision alone (Shields et al., 2000; Tuomaala, Eskelin, Tarkkanen, & Kivelä, 2002) .
Regional lymph node metastasis occurs in 15%-41% by a median of 2.3 years post-diagnosis, whereas systemic metastases (± regional nodes involvement) develop in 9%-25%, by just over 3 years. The 10-year CoM-related mortality is 18%-30% (Damato & Coupland, 2008; Shields et al., 2000; Tuomaala & Kivela, 2004; Werschnik & Lommatzsch, 2002) . Clinical and pathological predictors of metastasis include the following: non-bulbar tumor location, local tumor recurrence, epithelioid cell morphology, and a high mitotic count (Seregard, 1993; Shields et al., 2000; Tuomaala et al., 2002) . The molecular drivers of metastasis are largely unknown in CoM because of its rarity and because of the usual paucity of tissue available for detailed analysis.
Previous studies investigating CoM genetic abnormalities had variable, and often small, cohort sizes (n = 16-78), and mostly targeted hotspot mutations known to occur in cutaneous melanoma (CM), namely in BRAF, NRAS, KIT, and the TERT promoter described in on average 40%-50%, 15%-25%, 1%-3%, and ~70% of CM cases, respectively (Broekaert et al., 2010; Carr & Mackie, 1994; Curtin, Busam, Pinkel, & Bastian, 2006; Davies et al., 2002; Handolias et al., 2010; Horn et al., 2013; Huang et al., 2013; Moltara et al., 2018; van 't Veer et al., 1989) . In CoM, such mutations are reported in 8%-54%, 0%-18%, 0%-11%, and 32%, respectively (Beadling et al., 2008; El-Shabrawi, Radner, Muellner, Langmann, & Hoefler, 1999; Gear, Williams, Kemp, & Roberts, 2004; Goldenberg-Cohen et al., 2005; Griewank et al., 2013; Lake et al., 2011; Larsen et al., 2015; Populo, Soares, Rocha, Silva, & Lopes, 2010; Scholz et al., 2018; Spendlove et al., 2004) . Whole exome sequencing on a relatively small series of 5 CoMs identified mutually exclusive NF1, BRAF, and NRAS driver mutations in 20%, 60%, and 20% of samples, respectively, alongside other individual cancer-associated and epigenetic regulator mutations, such as those of EGFR and the TERT promoter (Swaminathan et al., 2017) . Most recently, a larger study using next-generation sequencing discovered mutations of NF1 in 21 of 63 (33%) CoMs, BRAF in 16 (25%), NRAS in 11 (17%), and KRAS in a single sample (Scholz et al., 2018) . Mutations in NF1 were mostly mutually exclusive with those in BRAF or NRAS although exact frequencies were not given (Scholz et al., 2018) . These recent findings are also consistent with CM where NF1 mutations occur in 12%-30%, and are generally mutually exclusive from tumors with BRAF and NRAS mutations (Cirenajwis et al., 2017; Hodis et al., 2012; Krauthammer et al., 2015) . In line with CM, a 4-group gene-specific mutation/triple wild type (wt) classification for CoM was proposed (Cancer Genome Atlas, Network, 2015; Scholz et al., 2018) .
In addition to mutations, gross or regional chromosomal copy number alterations (CNAs) in CoM have been reported including gains of 1q, 3, 4q, 6p, 8,11, 12p, 13q, 14p, 17q, and 22q and losses of 1p, 3q, 8p, 9p, 10, 11q, 12q, 13, 15p, 16p, and 17p (Dahlenfors, Tornqvist, Wettrell, & Mark, 1993; Griewank et al., 2013; McNamara, Felix, Davison, Fenton, & Kennedy, 1997; Swaminathan et al., 2017; Vajdic et al., 2003) . We have previously demonstrated chromosome (chr) 6p regional amplification using multiplex ligation-dependent probe amplification (MLPA), which detected CDKN1A and RUNX2 (both on 6p21.2) gains in 69% of 16 and 76% of 21 primary CoMs, respectively, and 75% and 100% of 4 metastatic CoM, respectively (Lake et al., 2011) . We also identified amplifications of MLH1 (3p22.1) and TIMP2 (17q25.3) in 75% of 4 and 83% of 6 metastatic CoM, respectively, as well as MGMT and ECHS1 (both on 10q26.3) deletions in 83% of the six metastatic samples (Lake et al., 2011) .
However, the overall prevalence of these CNAs in CoM and their correlation with disease characteristics and prognosis remain unclear. Lake et al did not reveal any association between 6p21.2 gains and histological cell type, age, sex, or survival (Lake et al., 2011) . In addition, no correlation between BRAF, NRAS or NF1 mutations and recurrence, metastasis, or mortality was found (Gear et al., 2004; Griewank et al., 2013; Lake et al., 2011; Larsen et al., 2016; Scholz exact, p ≤ 0.05). This enhanced insight into CoM biology is a step toward identifying patients at risk of metastasis and potential therapeutic targets for systemic disease.
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Significance
Conjunctival melanoma (CoM) is a rare but potentially fatal melanoma subtype. We analyzed copy number alterations, and their frequencies, in relation to tumor characteristics and patients' outcomes. We identified recurrent 10q deletions, which correlated with histological features of poor prognosis and metastatic risk. This finding should facilitate future development of disease-specific prognostic and therapeutic models. Sheng et al., 2015) . A strong association between BRAF mutation and sun exposure was determined in two reports (p ≤ 0.03; Griewank et al., 2013; Larsen et al., 2016) , and with clinical and pathological T1 stage (p = 0.007) in a single study (Larsen et al., 2016) . The data are divided with regard to BRAF mutations in relation to age and sex, with some authors reporting a significant correlation with male gender and age younger than 65 years (p ≤ 0.02; Larsen et al., 2016) , whereas others did not find any correlation between these parameters (Griewank et al., 2013; Scholz et al., 2018; Sheng et al., 2015) .
Hence, there was a clear need to study, in depth, the prevalence of various CNAs and their clinical significance in a large clinically welldefined CoM cohort with a genome-wide approach. This current multicenter collaborative project was established to examine one of the largest CoM cohorts using single nucleotide polymorphism (SNP) genotyping array, with the intention of defining key biomarkers of CoM metastatic risk, and to correlate these with clinico-histological features and clinical outcomes, in order to identify patients at risk of metastasis, and also potential therapeutic targets for systemic disease. (PAM) or conjunctival melanocytic intraepithelial neoplasia (C-MIN; Damato & Coupland, 2008) 
| MATERIAL S AND ME THODS

| Study design
| Data collection
| DNA extraction
For each sample, a 4-μm formalin-fixed paraffin-embedded (FFPE) H&E-stained section was examined to identify areas with greater than 90% tumor cells. DNA was extracted using QIAamp ® DNA Mini Kit (Qiagen, Crawley, UK) following a modified protocol as previously described by Lake et al. (2011) . The quality of extracted DNA was determined by a modified multiplex PCR, adapted from van Dongen et al. (2003) . PCR products were visualized on 2% agarose gels stained with 1X SYBR Safe (Invitrogen, Paisley, UK) using the BioDoc-It
Imaging System (Ultra-Violet Products Ltd., Cambridge, UK).
| SNP array
Affymetrix SNP 6.0 genotyping (Affymetrix, Santa Clara, CA) was performed at Atlas Biolabs (Berlin, Germany The SNP data for all tumors can be accessed in the international public repository Gene Expression Omnibus (GEO, http://www.ncbi.
nlm.nih.gov/geo; accession number GSE123011). 
| Mutation detection
| Data analysis
Data analysis was undertaken in three separate work packages as outlined below: and was excluded from the analyses. CNAs detected by PGS in the mutant tumors were compared to identify those unique to either mutation as described above. The list was further refined to include only oncogenes and TSGs as defined in UniProt.
Comparisons to CoMs that were wild type for both BRAF and NRAS were not performed as they may have included NF1 mutations, which we did not test for and would have likely confounded the results. Finally, to assess whether gene dosage was relevant to the mutation status, the amplification frequency of the BRAF and NRAS genes in the mutant groups was compared.
| Immunohistochemistry
The four significantly deleted TSGs, NEURL1, SUFU, PDCD4, and
C10orf90, identified in CoMs that metastasized were selected for immunohistochemical analyses. Four-µm thick FFPE tissue sections were used from available CoM samples. Fifteen sections were tested for NEURL1, 14 for SUFU and PDCD4, and 13 for C10orf90. Antigen retrieval and staining were performed as previously described by Lake et al. (2013) . Primary antibodies were as follows: anti-NEURL1 
| Statistical analyses
A Mann-Whitney test was used for non-parametric continuous variables and Pearson's chi-square/Fisher's exact for categorical variables.
Kaplan-Meier survival curves were used to assess metastasis-free survival and OS. Independent t test was used for immunohistochemistry (IHC) scoring comparisons. All analyses were performed using IBM SPSS Statistics software version 22, IBM, Chicago, IL. 
| RE SULTS
| Patients and demographics
| Identification of CNAs associated with CoM metastatic risk
No oncogenes or TSGs were identified in the CNAs exclusive to Kaplan-Meier survival curves on the 59 patients estimated this regional deletion to be significantly associated with lower metastasisfree survival (log-rank, p = 0.008, Figure 3 ), and this was confirmed in those 47 patients with FU ≥3.4 years (logistic regression, p = 0.005; 
| Correlation between CNAs and mutation status
Eighteen (34%) of the 53 CoM were BRAF-mt and 35 (66%) were BRAF wt, in keeping with published data. The mutations detected were as follows: V600E/EC in 15 samples (83%), V600K in two (11%), and V600R in one tumor (5%). NRAS mutations were detected in 6 (13%) of the 45 tested samples, of which five (83%) were in codon 61 and one (17%) in codon 12; 39 (87%) tumors were NRAS wt. BRAF and NRAS mutations were mutually exclusive except for the single tumor harboring the BRAF V600R mutation, which was also NRAS c61 mutant. After excluding the sample with concomitant BRAF and NRAS mutations, the 44 tumors in which both BRAF and NRAS mutations were analyzed, the mutation status was as follows:
BRAF-mt/NRAS wt in 14 (31%) tumors, BRAF wt/NRAS-mt in 5 (11%), and wt for both genes 25 (56%) tumors.
By comparing only the BRAF-mt and NRAS-mt tumors, no clinical or histological features were significantly associated (p > 0.05) with the mutation status (Table 2 ). Significant regional amplifications were observed on chr 17q in NRAS-mt tumors (Fisher's exact, p = 0.01) but did not include known oncogenes. In contrast, significant regional deletions were noted on chr 10q in BRAF-mt tumors (Fisher's exact, p ≤ 0.03), Supporting Information 
| Examining the effect of deletions on protein expression in selected samples
IHC protein expression localization and intensity scoring of the four significantly deleted TSGs in CoMs that metastasized showed: For all proteins, the difference between the means of scores in normal and deleted CN tumors was not statistically significant (independent t test, p > 0.05); hence, there was no effect of the deleted CNAs on the respective protein expression, Supporting Information 
| D ISCUSS I ON
This is the first study to date to characterize, in depth and in such a large clinically well-defined cohort, genome-wide CNAs, their differential frequencies, and relationship to clinico-histomorphological tumor features, BRAF/NRAS mutation, and clinical outcomes using high-resolution SNP array genotyping technology.
Amplifications of 6p21-25 were found in up to 61% of CoM in our cohort. Regional chr 6p amplification was previously identified by our group and others (Griewank et al., 2013; Lake et al., 2011; Swaminathan et al., 2017) , and has also been documented in CM (Höglund et al., 2004) . The Histone Cluster 1 (6p22.2) was the most common amplification in our study, which is implicated in various cancers and is thought to impact epigenetic and post-transcriptional modification (King, Waxman, & Stauss, 2008) , but was not associated with the clinical outcome in the current study.
In this study, we also identified novel regional and arm chromosomal losses on 9q, 16p, 17p, and 19, and more specifically of ASNS poor survival and inferior chemotherapeutic response (Lin et al., 2014) . In our study, ASNS did not correlate with the clinical outcome of our patients; however, there is scope to examine its role in the management of the ocular tumor or its secondaries.
Most intriguing in this study are the detected 10q deletions in CoM and their correlation with metastatic risk, of which 10q26.3 was also previously described by our group (Lake et al., 2011) . Our work has shown that regional deletions of chr 10q24. (Griewank et al., 2013) . These are well-recognized alterations in CM with implications on the oncogenic PI3K pathway inactivation and targeted therapy application (Isshiki, Elder, Guerry, & Linnenbach, 1993) , and, therefore, they are potentially pertinent to CoM druggable targets.
Broad regional chromosomal alterations were characteristic of CoM rather than single gene aberrations. It remains unclear whether such regional anomalies are "bystander" alterations subsequent to single gene loci or non-random events where the oncogenes and TSGs in the affected regions play roles at different stages of oncogenesis (Kwong & Chin, 2014 (Primdahl et al., 2002; Van Loo et al., 2010) .
The current study also provides further evidence supporting the similarities between CoM and skin melanoma. BRAF and NRAS mutation frequencies, and their mutual exclusivity, were comparable to CM (Curtin et al., 2005; Davies et al., 2002) , and in agreement with previous CoM reports ( Griewank et al., 2013; Larsen et al., 2016; Scholz et al., 2018) . We did not detect a correlation between the mutation status and clinical or histopathological features when compared to previous studies (Griewank et al., 2013; Larsen et al., 2016) . This could be explained by the difference in analytical methods.
We acknowledge the limitations of our study. First, with variable treatment regimens and follow-up times of the participating patients, it was not possible to assess the relationship between genetic alterations and CoM local recurrence. Nevertheless, the increased risk of metastasis following local CoM recurrence is well-known (Damato & Coupland, 2009 ). Long-term collaborative studies are essential to determine how radiation and topical chemotherapeutic methods could affect CoM biology. This should be undertaken as a future project when more samples become available. Second, the relation between chr 10q deletions and metastatic death was difficult to assess because of low number of events and the survival of some patients with metastases in our cohort. A prospective reanalysis of chr 10 and any related fatalities is warranted. Third, BRAF and NRAS mutations were tested by different techniques, and, as a result, their rarer mutations might have been missed in a small number of cases.
In addition, it is possible that tumors that were both BRAF wt and NRAS wt harbor NF1 or other RAS mutations, which were reported only after the completion of the current work (Scholz et al., 2018) . A follow-up study that incorporates all known CoM mutations is now needed to understand their significance in CoM pathogenesis.
In summary, we here present the most comprehensive profile of CNAs in a clinically well-defined CoM cohort to date and identified potential markers for metastatic risk and prognostication. The ultimate challenge remains to apply our current knowledge in the future development of prognostic models and effective therapeutics in metastatic CoM, as has been achieved in part with skin melanoma.
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